SCHEMBL3829265

SCHEMBL3829265

CCCc1cccc(O)c1-c1c(O)cccc1CCC

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ELANE P08246 3/20 0.51
CTSG P08311 3/20 0.51
IAPP P10997 4/20 0.46
HTR1A P08908 1/20 0.46
GABRA1 P14867 1/20 0.44
GABRB2 P47870 1/20 0.44
BID P55957 3/20 0.43
MCL1 Q07820 3/20 0.43
BCL2L1 Q07817 2/20 0.43
BAK1 Q16611 2/20 0.43
KAT8 Q9H7Z6 2/20 0.43
PPARG P37231 1/20 0.43
PPARA Q07869 1/20 0.43
EP300 Q09472 1/20 0.43
KAT2A Q92830 1/20 0.43
KAT2B Q92831 1/20 0.43
KAT5 Q92993 1/20 0.43
SAE1 Q9UBE0 1/20 0.43
ANPEP P15144 1/20 0.42
DPP4 P27487 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL982273 0.86 ELANE (0.45) ELANECTSGIAPPHTR1ABID
SCHEMBL3932355 0.86 ELANE (0.53) ELANECTSGIAPPHTR1ABID
SCHEMBL68921 0.82 IAPP (0.65) ELANECTSGIAPPGABRA1GABRB2
SCHEMBL3344675 0.81 GABRA1 (0.61) ELANECTSGIAPPGABRA1GABRB2
SCHEMBL30595395 0.81 HTR1A (0.64) HTR1AHSPA5
SCHEMBL51747 0.81 HTR1A (0.64) HTR1AHSPA5
SCHEMBL28615381 0.81 ELANE (0.48) ELANECTSGIAPPHTR1ABID
SCHEMBL1039776 0.80 TRPA1 (0.48) ELANECTSGIAPPHTR1AGABRA1
SCHEMBL218408 0.80 IAPP (0.44) ELANECTSGIAPPHTR1AGABRA1
SCHEMBL31290573 0.80 IAPP (0.44) ELANECTSGIAPPHTR1AGABRA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9315435-B2 Method for producing hydroxyphenylcyclohexanol compound SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2016-04-19 US disclosed
US-20150141707-A1 METHOD FOR PRODUCING HYDROXYPHENYLCYCLOHEXANOL COMPOUND SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2015-05-21 US disclosed
EP-2842930-A1 METHOD FOR PRODUCING HYDROXYPHENYLCYCLOHEXANOL COMPOUND Sumitomo Chemical Company Limited (JP) 2015-03-04 EP disclosed
EP-1586598-B1 Process for preparation of polymeric, phosphorus-containing compositions INVISTA TECH SARL (CH) 2009-09-09 EP disclosed
EP-1586598-A1 Process for preparation of polymeric, phosphorus-containing compositions E.I. du Pont de Nemours and Company (US) 2005-10-19 EP disclosed
EP-1571172-A1 Polymeric, phosphorus-containing compositions and their use in hydrocyanation, isomerization and hydroformylation reactions E.I. du Pont de Nemours and Company (US) 2005-09-07 EP disclosed
EP-1448668-A1 POLYMERIC, PHOSPHOROUS-CONTAINING COMPOSITIONS AND THEIR USE IN HYDROCYANATION, ISOMERIZATION AND HYDROFORMYLATION REACTIONS E. I. du Pont de Nemours and Company (US) 2004-08-25 EP disclosed
US-20030135014-A1 Polymeric, phosphorus-containing compositions and their use in hydrocyanation, isomerization and hydroformylation reactions INVISTA NORTH AMERICA S.A.R.L. 2003-07-17 US disclosed
WO-2003046049-A1 POLYMERIC, PHOSPHOROUS-CONTAINING COMPOSITIONS AND THEIR USE IN HYDROCYANATION, ISOMERIZATION AND HYDROFORMYLATION REACTIONS E. I. DU PONT DE NEMOURS AND COMPANY (US) 2003-06-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150141707-A1 METHOD FOR PRODUCING HYDROXYPHENYLCYCLOHEXANOL COMPOUND HSD11B2, CYP21A2, CYP11B2 ELANE 1834/4885CTSG 4431/4885IAPP 2629/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.